Related Experiment Video
Updated: Aug 9, 2026

Isolation, Characterization, and Proteomic Analysis of Plasma-Derived Extracellular Vesicles for Cardiovascular Biomarker Discovery
Published on: January 31, 2025
Plasma proteomics linking primary and secondary diseases: Insights into molecular mediation from UK Biobank data
Hanyu Qian1, Chao Wu2, Bo Li2
1Stanley and Judith Frankel Institute for Heart and Brain Health, University of Michigan Medical Center, Ann Arbor, MI, USA; Gilbert S. Omenn Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
Background:
Diabetes, hypertension, and dyslipidemia are major risk factors for cardiovascular, neurological, renal, and pulmonary diseases, yet clinically accessible molecular mediators linking these cardiometabolic conditions to downstream complications remain unclear.
Methods:
We analyzed plasma proteomic data from 53,030 UK Biobank participants with longitudinal follow-up. Mediation analysis evaluated circulating proteins linking three primary cardiometabolic diseases to 18 secondary outcomes. Mendelian randomization assessed potential causal relationships, and machine learning evaluated the predictive value of identified mediators.
Findings:
We identified 998 significant mediation pathways involving 337 unique plasma proteins. GDF15 consistently mediated associations between diabetes and cardiovascular diseases, and ACE2 linked poorly controlled diabetes to increased risk of nerve root and plexus disorders. Mediators were enriched in receptor-mediated signaling and molecular-interaction pathways. Mendelian randomization supported potential causal roles for 44 proteins. Incorporating mediator proteins into machine-learning models improved prediction of secondary disease risk beyond traditional clinical factors and other plasma proteins.
Conclusions:
Plasma proteins help mediate progression from cardiometabolic diseases to downstream complications. These findings provide a molecular map of disease mediation pathways, nominate biomarkers and therapeutic targets, and support improved risk stratification and targeted intervention.
Funding:
This this study was supported by the National Institutes of Health, the American Heart Association, and institutional funding.